{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T17:45:54Z","timestamp":1765302354978,"version":"3.46.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cystic fibrosis (CF) leads to chronic airway obstruction, inflammation, and infection, resulting in pulmonary exacerbations (PEx) that negatively impact lung function, quality of life, and mortality. The introduction of highly effective CFTR modulator therapy (HEMT) has improved outcomes in people with CF (pwCF), reducing the frequency of PEx and antibiotics. Using data from a single-center retrospective review and the Pediatric Health Information System (PHIS) database, this study evaluates the impact of HEMT on antibiotic utilization in pwCF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center, retrospective analysis was conducted comparing antibiotic use in the pre-ETI (2017-2019) and post-ETI (2020-2022) periods. Inclusion criteria were pwCF receiving care at for at least 1\u00a0year in both periods. Data on antibiotic agent, duration, and route of administration were collected. Additionally, a multicenter, retrospective study using the PHIS database was performed between January 2015 through June 2023, analyzing antibiotic utilization in hospitalized pwCF across multiple pediatric hospitals. Metrics included days of therapy (DOT) per 1000 patient days and length of stay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the single-center analysis, there was a 36.2% decrease in IV and 19.5% decrease in PO antibiotic use in the post-ETI period, with no change in treatment duration. In the PHIS analysis, antibiotic utilization decreased from the pre-ETI to post-ETI period, with reductions in anti-PsA and anti-MRSA agents and a decrease in length of stay. The median DOT per 1000 patient days decreased from 2257 (IQR: 1950, 2417) to 1710 (IQRL: 1371, 1909) (P\u00a0&amp;lt;\u2009.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The introduction of HEMT has led to reduction in antibiotic utilization for PEx among pwCF, at a single center and across multiple institutions. This decrease in antibiotic use highlights the potential for antibiotic stewardship programs to reassess and optimize antibiotic management in pwCF. Additional research is needed to determine the optimal duration and choice of antibiotics in the context of HEMT, with the goal of minimizing antibiotic exposure and associated risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpids\/piaf102","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:04:39Z","timestamp":1762520679000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the Impact of CFTR Modulator Therapy on Antibiotic Utilization: Insights From a Single Center Retrospective Review and Pediatric Health Information System Database"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0861-0124","authenticated-orcid":false,"given":"Stephanie R","family":"Duehlmeyer","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Children\u2019s Mercy Kansas City , Kansas City, MO ,","place":["United States"]},{"name":"School of Pharmacy, University of Missouri-Kansas City , Kansas City, MO ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7011-4826","authenticated-orcid":false,"given":"Ann L","family":"Wirtz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children\u2019s Mercy Kansas City , Kansas City, MO ,","place":["United States"]},{"name":"School of Pharmacy, University of Missouri-Kansas City , Kansas City, MO ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaina","family":"Burns","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children\u2019s Mercy Kansas City , Kansas City, MO ,","place":["United States"]},{"name":"School of Pharmacy, University of Missouri-Kansas City , Kansas City, MO ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M","family":"Oermann","sequence":"additional","affiliation":[{"name":"Division of Pediatric Pulmonology, Children\u2019s Mercy Kansas City , Kansas City, MO ,","place":["United States"]},{"name":"School of Medicine, University of Missouri-Kansas City , Kansas City, MO ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian R","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Missouri-Kansas City , Kansas City, MO ,","place":["United States"]},{"name":"Division of Pediatric Infectious Diseases, Children\u2019s Mercy Kansas City , Kansas City, MO ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua C","family":"Herigon","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Missouri-Kansas City , Kansas City, MO ,","place":["United States"]},{"name":"Division of Pediatric Infectious Diseases, Children\u2019s Mercy Kansas City , Kansas City, MO ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"2025120912413462700_ref1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1080\/03007995.2016.1277196","article-title":"Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States","volume":"33","author":"Rubin","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"2025120912413462700_ref2","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2025120912413462700_ref3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jcf.2024.04.004","article-title":"Update on the diagnosis and management of cystic fibrosis pulmonary exacerbations","volume":"23","author":"Cogen","year":"2024","journal-title":"J Cyst Fibros"},{"author":"Cystic Fibrosis Foundation","key":"2025120912413462700_ref4"},{"key":"2025120912413462700_ref5","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jcf.2020.02.012","article-title":"Finding the relevance of antimicrobial stewardship for cystic fibrosis","volume":"19","author":"Cogen","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2025120912413462700_ref6","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1093\/jpids\/piac071","article-title":"Antimicrobial stewardship in cystic fibrosis","volume":"11","author":"Lloyd","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2025120912413462700_ref7","doi-asserted-by":"publisher","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025120912413462700_ref8","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025120912413462700_ref9","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1164\/rccm.201207-1160oe","article-title":"Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2025120912413462700_ref10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jcf.2021.01.007","article-title":"Challenges in the use of highly effective modulator treatment for cystic fibrosis","volume":"20","author":"Ramos","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2025120912413462700_ref11","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/ph16030410","article-title":"Elexacaftor-tezacaftor-ivacaftor: A life-changing triple combination of CFTR modulator drugs for cystic fibrosis","volume":"16","author":"Bacalhau","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025120912413462700_ref12","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2025120912413462700_ref13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7812\/TPP\/21.089","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor on hospitalizations and intravenous antibiotic use","volume":"26","author":"Walter","year":"2022","journal-title":"Perm J"},{"key":"2025120912413462700_ref14","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/cid\/ciac117","article-title":"The rapid reduction of infection-related visits and antibiotic use among people with cystic fibrosis after starting elexacaftor-tezacaftor-ivacaftor","volume":"75","author":"Miller","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025120912413462700_ref15","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1164\/ajrccm.179.8.734a","article-title":"The impact of MRSA on lung function in patients with cystic fibrosis","volume":"179","author":"Sawicki","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2025120912413462700_ref16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1067\/mpd.2001.112897","article-title":"Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis","volume":"138","author":"Nixon","year":"2001","journal-title":"J Pediatr"},{"key":"2025120912413462700_ref17","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/ppul.26362","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on bacterial cultures from people with cystic fibrosis","volume":"58","author":"Beck","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2025120912413462700_ref18","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1164\/rccm.202102-0461OC","article-title":"A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment","volume":"204","author":"Goss","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2025120912413462700_ref19","doi-asserted-by":"publisher","first-page":"722483","DOI":"10.3389\/fped.2021.722483","article-title":"COVID-19 pandemic impact on respiratory infectious diseases in primary care practice in children","volume":"9","author":"Kaur","year":"2021","journal-title":"Front Pediatr"},{"key":"2025120912413462700_ref20","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.3390\/biomedicines10112771","article-title":"Impact of COVID-19 on lung disease in people with cystic fibrosis: A 6-month follow-up study on respiratory outcomes","volume":"10","author":"Medino","year":"2022","journal-title":"Biomedicines"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piaf102\/65240877\/piaf102.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/14\/12\/piaf102\/65240877\/piaf102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/14\/12\/piaf102\/65240877\/piaf102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T17:41:38Z","timestamp":1765302098000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/doi\/10.1093\/jpids\/piaf102\/8316754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piaf102","relation":{},"ISSN":["2048-7207"],"issn-type":[{"type":"electronic","value":"2048-7207"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,7]]},"article-number":"piaf102"}}